Ruthenium-Porphyrin Conjugates Show Potential for Anticancer Activity

Strategic Insights -

New research in the journal Dalton Transactions presents data on synthetic strategies for creating ruthenium-porphyrin conjugates with potential medicinal applications, including anticancer therapy. Investigators in Trieste, Italy have developed new classes of porphyrin-ruthenium conjugates, which combine the phototoxicity and tumour-localization properties of porphyrins with the cytotoxicity of metal fragments. The conjugates have shown promising results in studies, including cytotoxicity and photo-cytotoxicity tests.

Key Takeaways:

  • Researchers at the University of Trieste in Italy have developed new classes of porphyrin-ruthenium conjugates with potential bio-medical applications, particularly in anticancer therapy.
  • The conjugation of porphyrins to metal fragments is a strategy for making new compounds that combine phototoxicity and tumour-localization properties with cytotoxicity for additive antitumour effect.
  • The conjugates were prepared with peripheral pyridyl rings or through bpy units, with the number of Ru fragments attached ranging from 1 to 4 and total charge from -4 to +8.
  • Examples of conjugates include [Na](4)[4'TPyP{trans-RuCl(4)(dmso-S)}(4)] (2), which bears four NAMI-type Ru(III) fragments, and [4'TPyP{Ru([9]aneS3)(en)}(4)][CF(3)SO(3)](8) (3) and [bpy(4)-PP{Ru([9]aneS3)(dmso-S)}(4)][CF(3)SO(3)](8) (9), which have four half-sandwich Ru(II) compounds.
  • The Ru fragments may either contain labile ligands like in 2 or be coordinatively saturated and substitutionally inert, as in 3 or [bpy(4)-PP{Ru([12]aneS4)}(4)][CF(3)SO(3)](8) (11).
  • The ruthenium-porphyrin conjugates are moderately soluble in aqueous solution and are thus suitable for biological investigations, including cytotoxicity and photo-cytotoxicity tests.

Statistics:

  • 4 new classes of porphyrin-ruthenium conjugates were prepared in this study.
  • The number of Ru fragments attached to the porphyrins ranges from 1 to 4.
  • The total charge of the conjugates ranges from -4 to +8.
  • 2 examples of conjugates with four NAMI-type Ru(III) fragments are presented.
  • 2 examples of conjugates with four half-sandwich Ru(II) compounds are presented.
  • The Ru fragments may contain 1 or more labile ligands or be coordinatively saturated and substitutionally inert.

Sources:

  • Gianferrara, T., et al. "Synthetic strategies towards ruthenium-porphyrin conjugates for anticancer activity." Dalton Transactions 2009, 10742-56.
  • Biotech Week. "Ruthenium-Porphyrin Conjugates Show Potential for Anticancer Activity." 2010.